Hansoh Pharma - H (03692): I-DXd BLA withdrawal improves the competitive timing backdrop for Hansoh's Ris-Rez

Overview

This event note assesses what Merck and Daiichi Sankyo's withdrawal of the U.S. BLA for I-DXd means for Hansoh's B7-H3 ADC, Ris-Rez, in extensive-stage small-cell lung cancer. J.P. Morgan considers the competitive timing read-through favorable while emphasizing that global efficacy and safety replication remains necessary.

Core views

Merck/Daiichi voluntarily withdrew the U.S. BLA for B7-H3 ADC ifinatamab deruxtecan (I-DXd) in previously treated ES-SCLC after FDA discussions concluded that the supporting package, including Phase 2 IDeate-Lung01, did not meet accelerated-approval requirements. The BLA had priority review and an October 10, 2026 PDUFA date. J.P. Morgan views the withdrawal as incrementally positive for Hansoh/GSK's Ris-Rez because it removes part of I-DXd's near-term U.S. first-mover advantage. The firm does not regard the outcome as a negative verdict on B7-H3 biology; it sees the issue as the adequacy of this particular submission package. The report expects any new I-DXd filing to depend on the ongoing Phase 3 IDeate-Lung02 study. With enrollment nearing completion, a clinicaltrials.gov completion date in early 2028, and Phase 2 median overall survival of 10.3 months, J.P. Morgan considers an early-2028 refiling plausible. Ris-Rez has already delivered positive randomized China Phase 3 overall-survival data and is being tested in GSK's global Phase 3 EMBOLD SCLC-301 study, for which a readout could arrive in 2027 or 2028. A potential U.S. filing for Ris-Rez could therefore also occur in 2028. The report stresses that I-DXd's withdrawal does not de-risk Ris-Rez's own global regulatory path: the key question is whether its efficacy and safety profile can be reproduced in the global study. J.P. Morgan characterizes Ris-Rez as efficacy-leading based on China Phase 3 ARTEMIS-008 data in second-line-and-beyond ES-SCLC. Ris-Rez produced median overall survival of 18.5 months versus 10.3 months for topotecan, a hazard ratio of 0.46; median progression-free survival was 7.2 versus 3.0 months, and objective response rate was 58.3% versus 12.6%. I-DXd's Phase 2 dataset reported median overall survival of 10.3 months, median progression-free survival of 4.9 months and a 48.2% response rate overall; its 32-patient second-line subset reported 12.0 months, 5.6 months and 56.3%, respectively. While these figures appear favorable for Ris-Rez, the report explicitly cautions that different trial designs and patient populations prevent a head-to-head conclusion. Safety remains the principal debate. Ris-Rez had an 11.7% treatment-related interstitial lung disease rate in the WCLC presentation, with no grade 4 or 5 events. Tam-Peli reported 4.9% ILD/pneumonitis, while I-DXd reported 12.4% treatment-related ILD in Phase 2, including grade 3-or-higher events. J.P. Morgan therefore highlights not only ILD frequency but also its severity as B7-H3 ADC programs mature. Beyond the immediate event, J.P. Morgan's investment thesis is that Hansoh has evolved into an innovation-driven Chinese biopharma company positioned to benefit from out-licensing. It cites R&D investment supported by a commercial portfolio, a diversified oncology, immunology and neurology pipeline, and a record of multinational collaborations. The firm expects innovative-drug sales and licensing income to drive 12% and 15% CAGRs in revenue and earnings, respectively, through 2030E. Its HK$50.00 Dec-2027 target price is DCF-based and incorporates commercial innovative assets, late-stage pipeline assets, current and potential licensing income, pipeline value, cash and debt; assumptions include a roughly 3.8% risk-free rate, 9.6% WACC and 3.0% terminal growth rate.

Analysis framework

J.P. Morgan first evaluates the regulatory withdrawal's effect on the timing of competing B7-H3 ADC programs, then compares available efficacy and safety results while warning against direct cross-trial conclusions. It places the event within Hansoh's broader pipeline, out-licensing and DCF valuation thesis.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  The HK$50.00 Dec-2027 target price discounts expected contributions from commercial drugs, late-stage assets, licensing income, pipeline value, cash and debt using a 9.6% WACC and 3.0% terminal growth rate.

• Industry Analysis

  Cross-trial efficacy and safety comparison

  The report compares overall survival, progression-free survival, response rates and ILD outcomes across B7-H3 ADC studies, while noting that differences in trial design and patient populations preclude a head-to-head conclusion.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hansoh Pharma - H (3692.HK)

  Primary covered company; potential beneficiary of a reduced I-DXd first-mover advantage through its Ris-Rez program with GSK.

  Strengths

  Positive China Phase 3 Ris-Rez data, diversified innovative pipeline, commercial portfolio and out-licensing record.

  Weaknesses

  Global efficacy and safety replication for Ris-Rez has not yet been established.

  Comparison

  Ris-Rez's China Phase 3 efficacy metrics appear favorable versus reported I-DXd Phase 2 data, but the report does not consider this a valid head-to-head comparison.

  Risks

  Clinical trial failure, market-share erosion from new entrants or disruptive therapies, and geopolitical risks to out-licensing.

• GSK PLC (GSK.L)

  Partner in the global development of Ris-Rez through the EMBOLD SCLC-301 trial.

  Strengths

  Conducting the global Phase 3 study that could support a future filing.

  Risks

  Global Phase 3 efficacy and safety reproducibility remains uncertain.

Key data

• Ris-Rez median overall survival18.5 months versus 10.3 months for topotecanChina Phase 3 ARTEMIS-008 in 2L+ ES-SCLC; hazard ratio 0.46.
• Ris-Rez median progression-free survival7.2 months versus 3.0 months for topotecanChina Phase 3 ARTEMIS-008.
• Ris-Rez objective response rate58.3% versus 12.6%China Phase 3 ARTEMIS-008 versus topotecan.
• Ris-Rez treatment-related ILD11.7%No grade 4 or 5 events reported in the WCLC presentation.
• I-DXd treatment-related ILD12.4%Phase 2 data included grade 3-or-higher events.
• Hansoh target priceHK$50.00Dec-2027 DCF-based target price.
• DCF assumptions9.6% WACC; approximately 3.8% risk-free rate; 3.0% terminal growth rateJ.P. Morgan valuation assumptions.

Impact & implications

The withdrawal delays I-DXd's near-term U.S. regulatory route and may place a future I-DXd filing in the same year as a potential Ris-Rez U.S. filing. J.P. Morgan sees this as favorable for Hansoh's competitive positioning, but not as validation of Ris-Rez's global approval prospects; global Phase 3 efficacy and safety evidence remains decisive.

Risks

• Clinical trial failure could undermine Hansoh's pipeline value.
• New entrants and disruptive therapeutic innovations could erode market share.
• Geopolitical developments could hinder out-licensing opportunities.
• Ris-Rez must reproduce its efficacy and safety profile in the global Phase 3 study.

What to watch

• Completion and eventual results of I-DXd's Phase 3 IDeate-Lung02 study and the timing of any new U.S. BLA filing.
• The 2027 or 2028 readout from GSK's global Phase 3 EMBOLD SCLC-301 trial for Ris-Rez.
• ILD incidence and severity across maturing B7-H3 ADC programs.
• Hansoh's FY25 commercial drug sales, late-stage B7-H3 ADC, B7-H4 ADC and GLP-1/GIP data readouts, and additional out-licensing deals.